IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(10), P. 2450 - 2450

Published: Oct. 11, 2023

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with significant negative impact on the quality of life patients. To date, therapeutic landscape for management has been extremely limited, resulting in profound unmet need. Indeed, adalimumab, an anti-tumor necrosis factor (TNF)-α monoclonal antibody, only approved biologic agent HS, obtaining response 50% HS Numerous clinical trials are currently ongoing to test novel targets HS. The IL-17-mediated cascade target several agents that have shown efficacy and safety treating moderate-to-severe Both bimekizumab secukinumab, targeting IL-17 different manners, successfully completed phase III promising results; latter recently by EMA treatment aim this review summarize current state knowledge concerning relevant role pathogenesis, highlighting key evidence anti-IL-17 disease.

Language: Английский

---

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta‐analysis of phase III trials

Journal of the European Academy of Dermatology and Venereology, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

Phase III clinical trials are designed to evaluate the therapeutic effect of drugs and their superiority over other treatment methods, but biologics for hidradenitis suppurativa (HS) have not been compared head-to-head in phase studies. To relative efficacy safety HS a network meta-analysis including available data from trials. MEDLINE Embase were searched investigating and/or at least one biologic moderate-to-severe HS. The odds ratios reaching an Clinical Response 50 (HiSCR50) occurrence adverse events after 12-16 weeks between treatments. PIONEER I II (adalimumab 40 mg weekly vs. placebo), SUNSHINE SUNRISE (secukinumab 300 every 2 4 placebo) as well BE HEARD (bimekizumab 320 with 2731 patients included. Adalimumab was ranked most effective HiSCR50 significant secukinumab (OR = 1.74; 95% confidence interval [CI]: 1.11-2.73) 1.72; CI: 1.09-2.7) insignificant bimekizumab 1.23; 0.74-2.06) 1.25; 0.73-2.14). showed fewest 0.52; 0.32-0.86) 0.79; 0.47-1.33) 0.69; 0.45-1.07) 0.71; 0.46-1.1). Among currently approved agents HS, adalimumab demonstrated highest first treatment.

Language: Английский

---

Biology of Interleukin-17 and Novel Therapies for Hidradenitis Suppurativa

Journal of Interferon & Cytokine Research, Journal Year: 2023, Volume and Issue: 43(12), P. 544 - 556

Published: Oct. 12, 2023

Skin disorders affect ∼40% of the human population. One most debilitating cutaneous is Hidradenitis suppurativa (HS), a noncommunicable chronic inflammatory disease with an estimated global prevalence 0.4% to 2.5%. In January 2011, high levels IL-17 were discovered in skin lesions HS patients. following years, translational and clinical research led better understanding pathogenesis HS. June 2023, more than 12 years after initial note, secukinumab, anti-IL-17A monoclonal antibody, was approved for treatment moderate severe This next milestone improving these patients approval anti-TNF-α antibody adalimumab 2015. this review article, we present pathway discuss use secukinumab as therapeutic option disease. Our starts description epidemiology, features, etiology, An overview IL-17/IL-17 receptor system general detailed known facts about expression action follow. Afterward, consider results trials evaluating safety efficacy inhibitors Finally, comparison made between characteristics that may be particularly suitable each biologics are described.

Language: Английский

---

Comparative efficacy and therapeutic positioning of biologics in hidradenitis suppurativa: A systematic review with network meta-analysis of randomised trials

Indian Journal of Dermatology Venereology and Leprology, Journal Year: 2024, Volume and Issue: 90, P. 302 - 310

Published: Feb. 28, 2024

Background Hidradenitis suppurativa (HS) is a challenging inflammatory skin condition. Recently, many different biologics have been tested for HS, but the paucity of head-to-head comparative trials makes it difficult to determine real value each biological intervention. We aimed relative efficacy among in treating moderate-to-severe HS throughout network meta-analysis (NMA) and, identify which pathogenetic pathways may be most appropriate target. Methods comprehensively identified studies 3 databases and clinicaltrials.gov. The eligibility criteria included randomised controlled (RCTs) reporting data on HS. Results NMA comprised 13 comprising 14 interventions 2,748 participants network. showed odds achieving clinical response were significantly superior with adalimumab (RR: 0.37, 95% CI = 0.06–0.63), QW 0.63, 0.43–0.87), MAB1p 1.33, 0.03–3.12), secukinumab 0.25, 0.11–0.47) secukinumabQ2W 0.24, 0.1–0.46) compared placebo. Conclusion Based NMA, inhibiting tumour necrosis factor (TNF)-a appears best strategy, followed by blockade IL--17 secukinumab. Data bimekizumab CJM112 are promising. Infliximab has inconsistent response, more necessary confirm this molecule as potential third-line therapy IL-23 CD5a not relevant, or at least current evidence insufficient recommend further investigation guselkumab, risankizumab, vilobelimab phase III trials.

Language: Английский

---

Hidradenitis supurativa

Medicina Clínica, Journal Year: 2023, Volume and Issue: 162(4), P. 182 - 189

Published: Nov. 13, 2023

Language: Английский

---

Is there a surgical window of opportunity in hidradenitis suppurativa?

International Wound Journal, Journal Year: 2024, Volume and Issue: 21(6)

Published: June 1, 2024

We have been following the publications of your journal and would like to contribute knowledge generated through it. In text, we will talk about hidradenitis suppurativa (HS), a pathology on which focus research is nowadays, due great morbidity it entails therapeutic alternatives that are emerging, especially those related new biological drugs directed against specific targets involved in pathogenesis disease.1, 2 As well known, chronic inflammatory disease hair follicle affects body regions with apocrine glands, axillae anogenital area. Its progressive destructive nature, causes irreversible damage, stands out.3 carried out study aim evaluate whether early surgical treatment, stages disease, associated less aggressive interventions. For this purpose, designed cohort including patients moderate severe who underwent wide excision closure by secondary intention. Disease progression was assessed duration, structural damage Hurley stage, severity IHS4 aggressiveness intervention cm2 skin excised.4 A total 80 were included, mean age 35.91 (11.33) years male:female ratio 29:51. The duration 12.28 (9.35) years, 80% (64/80) stage II 20% (16/80) III. according 7.73 (4.36), recurrence rate at 68 weeks follow-up 23.75% (19/80) excised area 24.78 (11.79) cm2. observed longer (p < 0.05), II-III 0.02) higher score 0.01) correlated more (see Figure 1). This led 0.1). say just as there medical window opportunity treatment can avoid surgery,5 probably also opportunity. Early proactive likely involve extensive surgery better medium-term outcomes

Language: Английский

---

The Endo-lift Laser (Intralesional 1470 nm Diode Laser) for Dermatological Aesthetic Conditions: A Systematic Review

Aesthetic Plastic Surgery, Journal Year: 2024, Volume and Issue: unknown

Published: June 17, 2024

Language: Английский

---

Essentials of hidradenitis suppurativa: a comprehensive review of diagnostic and treatment perspectives

Annals of Medicine and Surgery, Journal Year: 2024, Volume and Issue: unknown

Published: June 28, 2024

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurring nodules, abscesses, and subcutaneous sinus tracts scars, imposing significant psychological burden diminishing quality of life for patients. The pathophysiology HS remains poorly understood, with lifestyle, genetic, hormonal factors implicated in its development. Until recently, therapeutic options were limited, adalimumab being the sole FDA-approved biologic drug HS. However, approval secukinumab, new possibilities have emerged treating this challenging condition. complex pathogenesis wide clinical manifestations make management challenging, often requiring combination treatments tailored to disease severity. While lifestyle modifications, topical treatments, oral antibiotics suffice managing mild cases, moderate-to-severe presents challenge due poor response traditional approaches. In comprehensive review, we analyze various evaluation tools therapy strategies available diagnosis treatment HS, drawing insights from published literature guide clinicians addressing complexities debilitating disease.

Language: Английский

---

Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes—A Review of the Literature

Medicina, Journal Year: 2024, Volume and Issue: 60(9), P. 1465 - 1465

Published: Sept. 6, 2024

The management of hidradenitis suppurativa (HS) in elderly patients presents unique challenges due to its chronic inflammatory nature, heterogeneous clinical presentation and comorbidities. While HS typically affects the anogenital intertriginous regions, may exhibit atypical features such as involvement neck, mammary area gluteal region. prevalence population is lower average age disease onset higher than under 65. In contrast, it unclear whether has different features. frequently present multiple comorbidities, including obesity, diabetes, heart disease, which further complicate decisions. Therapeutic interventions must consider frailty increased risk multimorbidity adverse events patients. systemic antibiotics remain a mainstay treatment, biologic agents TNFα inhibitors secukinumab offer promising options for refractory cases. However, their safety efficacy patients, particularly those with require careful consideration. A comprehensive approach managing involves not only pharmacological but also lifestyle modifications surgical where appropriate. Multidisciplinary collaboration between dermatologists, geriatricians other specialists essential tailoring treatment strategies optimizing long-term outcomes quality life special population.

Language: Английский

---

Hidradenitis suppurativa

Medicina Clínica (English Edition), Journal Year: 2024, Volume and Issue: 162(4), P. 182 - 189

Published: Feb. 1, 2024

---